MedTrace Logo

A Study of the Efficacy and Safety of 2PX in Patients With Pain Due to Osteoarthritis of the Knee

NCT00954629 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2010-03-24

No results posted yet for this study

Summary

The purpose of the study is to demonstrate the superiority of topically administered 2PX versus placebo (vehicle) control in terms of reduction in pain intensity and physical function.

Conditions

Interventions

DRUG

strontium chloride hexahydrate

Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.

DRUG

Placebo

Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.

Sponsors & Collaborators

  • SantoSolve AS

    collaborator INDUSTRY

  • Smerud Medical Research International AS

    lead OTHER

Principal Investigators

  • Stuart Ratcliffe, MD · MAC Neuroscience centre in Blackpool, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Finland
  • Poland
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00954629 on ClinicalTrials.gov